Stevens Christopher James 4
4 · ROCKET PHARMACEUTICALS, INC. · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
Rocket Pharmaceuticals (RCKT) COO Christopher J. Stevens Receives Awards
What Happened Christopher J. Stevens, Chief Operating Officer of Rocket Pharmaceuticals, was granted equity awards on February 11, 2026: 61,963 restricted stock units (RSUs) and a derivative grant representing the right to acquire 93,037 shares. Both entries are reported as acquired at $0.00 in the Form 4 (i.e., grants/awards rather than open‑market purchases or sales).
Key Details
- Transaction date: 2026-02-11; Filing date: 2026-02-13 (timely filing).
- Grants reported: 61,963 RSUs (award A) and a derivative grant for 93,037 shares (award A), both with acquisition price $0.00.
- Shares owned after transaction: not explicitly stated in the provided filing excerpt; note F1 indicates holdings include RSUs that convert one-for-one to common stock.
- Vesting / footnotes:
- F2 (RSUs): 1/3 vests on Feb 11, 2027; remaining shares vest in equal quarterly installments over the next two years.
- F3 (option/derivative): the 93,037-share right vests on the same schedule — 1/3 on Feb 11, 2027, then quarterly over two years, subject to continued employment.
- No indication of immediate sale or cashless exercise in this filing.
Context These are compensation awards (RSUs and a time‑vesting option-like grant) rather than purchases or sales. RSUs convert to common shares 1:1 when vested; the derivative grant represents the right to purchase shares upon vesting. Such grants are routine for executive compensation and do not by themselves indicate trading sentiment.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2026-02-11+61,963→ 469,129 total - Award
Stock Option (Right to Buy)
[F3]2026-02-11+93,037→ 93,037 totalExercise: $3.24Exp: 2036-02-11→ Common Stock (93,037 underlying)
Footnotes (3)
- [F1]Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
- [F2]Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.
- [F3]This option represents a right to purchase a total of 93,037 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.